A bruised Cir­cas­sia of­floads debt by re­turn­ing COPD drugs to As­traZeneca

It had a glit­ter­ing £200 mil­lion mega-IPO on the Lon­don Stock Ex­change in 2014, but fail­ure af­ter tri­al fail­ure blight­ed its prospects. A bat­tered Cir­cas­sia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER